Resource impact statement

No significant resource impact is anticipated

We do not expect this guidance to have a significant impact on resources; that is, it will be less than £5m per year in England (or £9,100 per 100,000 population). Etelcalcetide is a treatment option when treatment with a calcimimetic is indicated, but cinacalcet is not suitable. The population treated with etelcalcetide is estimated to be around 1,800 for England.

The list price of etelcalcetide has a discount that is commercial in confidence. Any enquiries from NHS organisations about the patient access scheme should be directed to Jean-Gabriele Castaigne on or 01223 436439, or to Kawitha Helme on or 01895 525515.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.

This page was last updated: 28 June 2017